Thomas A. Zalewski - 18 May 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Chief Legal Officer
Issuer ticker: AQST
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 12:02:01 UTC
Prior SEC filing: 10 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Hillary T. Yegen, as Attorney-in-Fact for Thomas Zalewski

Key filing fact

Thomas A. Zalewski filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 19 May 2026.

Key facts

This page summarizes Thomas A. Zalewski's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 May 2026, 12:02.

Change

Previous filing in this sequence was filed on 10 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127796 Primary reporting owner

Zalewski Thomas A.

Relationship: Chief Legal Officer
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Hillary T. Yegen, as Attorney-in-Fact for Thomas Zalewski
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +75,000
Change %
Price: $0.000000^*
Shares after: 75,000
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $4.14
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Footnote F2

The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.